-
1 Comment
Kymera Therapeutics, Inc is currently in a long term downtrend where the price is trading 3.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.1.
Based on the above factors, Kymera Therapeutics, Inc gets an overall score of 1/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for KYMR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
